WO2000027996A1 - Serum free medium for chondrocyte-like cells - Google Patents

Serum free medium for chondrocyte-like cells Download PDF

Info

Publication number
WO2000027996A1
WO2000027996A1 PCT/EP1999/008482 EP9908482W WO0027996A1 WO 2000027996 A1 WO2000027996 A1 WO 2000027996A1 EP 9908482 W EP9908482 W EP 9908482W WO 0027996 A1 WO0027996 A1 WO 0027996A1
Authority
WO
WIPO (PCT)
Prior art keywords
serum free
free medium
medium
serum
fgf
Prior art date
Application number
PCT/EP1999/008482
Other languages
French (fr)
Inventor
Ranieri Cancedda
Beatrice Dozin
Original Assignee
Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate
Istituto Nazionale Per La Ricerca Sul Cancro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate, Istituto Nazionale Per La Ricerca Sul Cancro filed Critical Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate
Priority to IL14291499A priority Critical patent/IL142914A0/en
Priority to JP2000581163A priority patent/JP2002529071A/en
Priority to AU13804/00A priority patent/AU758073B2/en
Priority to US09/831,161 priority patent/US6617159B1/en
Priority to EP99971844A priority patent/EP1131407B1/en
Priority to CA002348687A priority patent/CA2348687A1/en
Priority to DE69933579T priority patent/DE69933579D1/en
Publication of WO2000027996A1 publication Critical patent/WO2000027996A1/en
Priority to IL142914A priority patent/IL142914A/en
Priority to US10/614,191 priority patent/US7109032B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Definitions

  • Bone and cartilage transplantation is an absolute need in reconstruction of bone and cartilage segments in plastic surgery, traumatic surgery or after the removal of neoplastic lesions, etc.
  • material of human (autologous, from donors or from cadavers) or animal origin has been used for this purpose.
  • tissue transplantation the increased need for microbial safety in tissue transplantation, the advances in cell biology, cell differentiation and tissue engineering, the concept of rebuilding tissues from autologous or allogeneic cells expanded in vitro has become a growing field in the world of biomedical sciences.
  • Cellular sources for skeletal repair include chondrocytes and cells committed to the chondrocyte lineage, and mesenchymal stem cells, the former specific for cartilage, the latter multipotential and therefore having the potential to be used to replace bone, cartilage and other tissues.
  • Mesenchymal stem cells are found in bone marrow as well as in blood, dermis and periosteum. Although these cells are normally present at very low frequencies in bone marrow, these cells can be isolated purified and culturally expanded, for example, as described in U.S. Patent No. 5,486,359.
  • chondrocytes and MSCs typically take place in culture medium supplemented with bovine serum or optimally with autologous serum from the patient.
  • bovine serum or optimally with autologous serum from the patient.
  • animal or autologous serum in chondrocyte and MSC cultures has certain disadvantages and limitations in view of the potential therapeutical applications of these cultures.
  • serum is not the physiological fluid most cells closely contact in tissue in vivo. This is particularly true for chondrocytes that, in vivo, are embedded in their avascularized matrix and rely for their own growth and differentiation on various growth factors and cytokines acting in an autocrine/panacrine manner rather than diffusing from the distant bloodstream.
  • serum substitutes for culturing cells for potential in vivo therapeutic applications is desirable.
  • the present invention provides a serum substitute for culturing cells in vitro using well defined factors able to support cell viability, proliferation and differentiation as effectively as serum containing medium.
  • the cells are articular chondrocytes or mesenchymal stem cells.
  • the invention comprises a composition for the expansion of chondrocytes, comprising a minimum essential medium, a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, and insulin.
  • the serum free growth medium for chondrocytes comprises FGF-2 as a growth factor, linoleic acid as the lipid/fatty acid source, ascorbic acid and ⁇ -mercaptoethanol as antioxidants, holo- and apo-transferrin as the iron source, and dexamethasone as a steroid.
  • Optional ingredients can include cholesterol, trace metals such as selenium, and vitamins such as biotin and sodium pantotenate.
  • the invention comprises a composition for the maintenance of mesenchymal stem cells, comprising a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, one or more vitamins, one or more trace metals, and IGF-1 , in combination with a minimum essential medium.
  • the serum free growth medium for mesenchymal stem cells comprises FGF-2, LIF and SCF as growth factors, sodium pantotenate and biotin as vitamins, and selenium as a trace metal.
  • the present invention provides serum free compositions suitable for chondrocyte and mesenchymal stem cell growth and proliferation.
  • the compositions may include in a base minimum essential medium, such as Coon's modified Ham's F-12 medium, the following components as a substitute for serum: i) one or more growth factors or proteins which cause resting cells to undergo cell division and/or differentiation, such as insulin, FGF-2, PDGFbb, EGF, LIF and SCF and IGF-1 ; ii) one or more steroids such as dexamethasone; iii) one or more sources of lipids and fatty acids, necessary for cell membrane biosynthesis, such as cholesterol and linoleic acid; and iv) an iron source such as transferrin.
  • a base minimum essential medium such as Coon's modified Ham's F-12 medium
  • the following components as a substitute for serum: i) one or more growth factors or proteins which cause resting cells to undergo cell division and/or differentiation, such as insulin, FGF-2, PDGF
  • FGF-2, PDGFbb and EGF are potent mitogens for cells of mesenchymal origin.
  • Dexamethasone is known to ' keep cells in a cycling phase in vitro.
  • the serum free medium of the present invention may further comprise: i) albumin (preferably of mammalian species) which functions as an aspecific carrier; ii) one or more antioxidants such as ⁇ -mercaptoethanol; iii) a supplement for coenzyme transport in carboxyl group transfer reactions, such as biotin; iv) trace elements as a supplemental source of metal necessary for electron transport and many metalloenzymes and proteins, such as selenium; v) vitamins, such as biotin and pantotenate; and vi) ascorbic acid, to facilitate organization of the extracellular matrix.
  • albumin preferably of mammalian species
  • one or more antioxidants such as ⁇ -mercaptoethanol
  • a supplement for coenzyme transport in carboxyl group transfer reactions such as biotin
  • trace elements as a supplemental source of metal necessary for electron transport and many metalloenzymes and proteins, such as selenium
  • vitamins such as biotin and pantotenate
  • ascorbic acid to facilitate
  • Insulin and dexamethasone are added at the average concentrations usually reported in the literature.
  • IGF-I, LIF and SCF are present at concentrations in the range from about
  • the defined components comprise EGF,
  • FGFbb and FGF-2 ascorbic acid, linoleic acid, human serum albumin (HSA), ⁇ -mercaptoethanol, dexamethasone, insulin, human holo- and apo- transferrin.
  • FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 1 to about 10 ng/ml. In a preferred embodiment, FGF-2, PDGFbb and EGF are present at concentrations of from
  • the defined components comprise : EGF, PDGFbb and FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, ⁇ -mercaptoethan ⁇ l, dexamethasone, human holo- and apo- transferrin, selenium, biotin, sodium pantotenate.
  • FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 5 ng/ml to- about 10 ng/ml of each factor. The preferred concentrations of FGF-2, PDGFbb and EGF are 10 ng/ml.
  • FGF-2 alone was found to be the most active factor for maintenance of osteochondrogenic potential in MSCs.
  • Example 1 Articular cartilage was harvested from the knee joint of young adult human donors. The samples were first cleaned of any adherent muscular, connective or subchondral bone tissues, minced into l -3mm fragments and rinsed in PBS. Single chondrocytes were then released by repeated enzymatic digestions at 37°C with 0.25% trypsin, 400U/ml collagenase I, l OOOU/ml collagenase II and 1 mg/ml hyaluronidase. Trypsin was then blocked and removed by rapid and extensive washes in PBS containing soybean trypsin inhibitor.
  • Cells were plated in anchorage-dependent conditions in Coon's modified Ham's F-12 medium supplemented either with 10% fetal calf serum (FCS, control culture) or the following defined components: EGF, PDGFbb and FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), ⁇ - mercaptoethanol, dexamethasone, insulin, human holo- and apo-transferrin.
  • FCS fetal calf serum
  • Table 1 below shows the preferred amounts of each component.
  • Insulin may not be substituted with IGF-1 in the medium for chondrocytes. Insulin was preferably at a concentration of 5 ⁇ g/ml.
  • Bone marrow sample harvested from the iliac crest of the patient was washed twice with PBS.
  • the nucleated cells were counted using methyl violet and plated at 5xl0 6 cells as unfractionated marrow per 10 cm tissue culture dish.
  • the cells were maintained in Coon's modified Ham's F12 (F12) supplemented either with 10% FCS and 1 ng/ml
  • FGF-2 control culture or the following defined components: EGF, PDGFbb,
  • FGF-2 FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, ⁇ -mercaptoethanol, dexamethasone, human holo- and apo-transferrin, selenium, biotin and sodium pantotenate.
  • Table 2 shows the preferred amounts of each component.
  • the cells were first plated for 48 hours in F12 medium supplemented with 10% human serum and 1 ng/ml FGF-2.
  • FGF-2 alone was the most active factor for maintenance of osteochondrogenic potential in mesenchymal stem cells.
  • Selenium, biotin and sodium pantotenate were preferably included for cell viability.
  • LIF and SCF were seen to improve the extent of cell proliferation, in particular in combination with IGF-1.
  • EGF/PDGF/FGF-2 1 - 10 ng/ml
  • MTT Thiazolyl blue staining. Briefly, culture medium was removed and replaced with 0.5 ml of medium without supplement; then 25 ⁇ l MTT (Sigma,
  • Example 4 The differentiation potential of the chondrocytes expanded in serum free conditions was tested both in vitro and in vivo.
  • the expanded cells were transferred in anchorage-independent conditions and maintained as a pellet culture for 2-4 weeks in the serum free medium previously shown by Johnstone et al. (Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M. and Yoo, J.U. Exp. Cell Res. 238, 265-272, 1998) to induce chondrogenesis of serum expanded MSCs.
  • the expanded cells were implanted for 2 to 8- weeks in athymic mice either as a dense cell suspension or after embeddment in fibrin gel (Tissucol).
  • the samples were fixed in formalin, embedded in paraffin and sectioned. Serial sections were processed for histological (toluidine blue and alcian blue) analysis and immunohistochemistry with collagen-specific antibodies.
  • FCS a total absence of full chondrogensis was observed both in vitro and in vivo; at most, a faint metachromatic staining was detected in some pellet cultures, but they always lacked well defined lacunae and well organized extracellular matrix.
  • Example 5 The osteogenic potential of MSCs after expansion under serum free defined conditions was tested in vivo by implantation of the expanded cells in athymic mice after adsorption on collagraft.
  • the medium contained Coon's modified Ham's F-12, dexamethasone, FGF-2, PDGFbb, EGF, transferrin, cholesterol, human serum albumin, biotin, selenium, Na pantotenate and ascorbic acid (concentrations as in Table 2).
  • the combinations tested were 1) insulin; 2) IGF-1 ; 3) insulin and LIF; 4) insulin and SCF; 5) insulin, LIF and SCF; 6) IGF-1 and LIF; 7) IGF- 1 and SCF; and 8) IGF-1 , LIF and SCF.
  • the samples were decalcified, included and processed for histology as above.
  • the sections were stained with hematoxylin-eosin. All the conditions of expansion allowed the MSCs to reform bone tissue in vivo; however, the amount of bone formed varied from condition to condition.
  • the combination of IGF-1 , LIF and SCF provided an optimal expansion environment among the combinations tested.

Abstract

The present invention provides serum free media for growth and proliferation of chondrocytes and mesenchymal stem cells in culture.

Description

SERUM FREE MEDIUM FOR CHONDROCYTE-LIKE CELLS
BACKGROUND OF THE INVENTION
Bone and cartilage transplantation is an absolute need in reconstruction of bone and cartilage segments in plastic surgery, traumatic surgery or after the removal of neoplastic lesions, etc. Typically, material of human (autologous, from donors or from cadavers) or animal origin has been used for this purpose. Given the increased demand from clinicians for transplant tissues, the increased need for microbial safety in tissue transplantation, the advances in cell biology, cell differentiation and tissue engineering, the concept of rebuilding tissues from autologous or allogeneic cells expanded in vitro has become a growing field in the world of biomedical sciences.
Cellular sources for skeletal repair include chondrocytes and cells committed to the chondrocyte lineage, and mesenchymal stem cells, the former specific for cartilage, the latter multipotential and therefore having the potential to be used to replace bone, cartilage and other tissues. Mesenchymal stem cells (MSCs) are found in bone marrow as well as in blood, dermis and periosteum. Although these cells are normally present at very low frequencies in bone marrow, these cells can be isolated purified and culturally expanded, for example, as described in U.S. Patent No. 5,486,359.
Typically, the in vitro expansion of chondrocytes and MSCs takes place in culture medium supplemented with bovine serum or optimally with autologous serum from the patient. However, the presence of animal or autologous serum in chondrocyte and MSC cultures has certain disadvantages and limitations in view of the potential therapeutical applications of these cultures. For example, serum is not the physiological fluid most cells closely contact in tissue in vivo. This is particularly true for chondrocytes that, in vivo, are embedded in their avascularized matrix and rely for their own growth and differentiation on various growth factors and cytokines acting in an autocrine/panacrine manner rather than diffusing from the distant bloodstream. Further, there is often high variability between animal serum batches. Extensive serum screening required to select the batch most representative of the in vivo inductive effects can be time-consuming and expensive The preparation of autologous serum from patients is also time consuming and supplies are limited. Animal serum can further potentially carry unknown pathogens with consequent risk of contamination for the patient.
Thus, serum substitutes for culturing cells for potential in vivo therapeutic applications is desirable.
SUMMARY OF THE INVENTION The present invention provides a serum substitute for culturing cells in vitro using well defined factors able to support cell viability, proliferation and differentiation as effectively as serum containing medium. In a preferred embodiment, the cells are articular chondrocytes or mesenchymal stem cells.
In one aspect, the invention comprises a composition for the expansion of chondrocytes, comprising a minimum essential medium, a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, and insulin. In a particularly preferred embodiment, the serum free growth medium for chondrocytes comprises FGF-2 as a growth factor, linoleic acid as the lipid/fatty acid source, ascorbic acid and β-mercaptoethanol as antioxidants, holo- and apo-transferrin as the iron source, and dexamethasone as a steroid. Optional ingredients can include cholesterol, trace metals such as selenium, and vitamins such as biotin and sodium pantotenate.
In another aspect, the invention comprises a composition for the maintenance of mesenchymal stem cells, comprising a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, one or more vitamins, one or more trace metals, and IGF-1 , in combination with a minimum essential medium. In a particularly preferred embodiment, the serum free growth medium for mesenchymal stem cells comprises FGF-2, LIF and SCF as growth factors, sodium pantotenate and biotin as vitamins, and selenium as a trace metal.
BRIEF DESCRIPTION OF THE DRAWING Figure 1 shows the comparison of articular chondrocyte growth kinetics in medium containing FCS and the serum free medium of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides serum free compositions suitable for chondrocyte and mesenchymal stem cell growth and proliferation. The compositions may include in a base minimum essential medium, such as Coon's modified Ham's F-12 medium, the following components as a substitute for serum: i) one or more growth factors or proteins which cause resting cells to undergo cell division and/or differentiation, such as insulin, FGF-2, PDGFbb, EGF, LIF and SCF and IGF-1 ; ii) one or more steroids such as dexamethasone; iii) one or more sources of lipids and fatty acids, necessary for cell membrane biosynthesis, such as cholesterol and linoleic acid; and iv) an iron source such as transferrin.
FGF-2, PDGFbb and EGF are potent mitogens for cells of mesenchymal origin. Dexamethasone is known to' keep cells in a cycling phase in vitro.
The serum free medium of the present invention may further comprise: i) albumin (preferably of mammalian species) which functions as an aspecific carrier; ii) one or more antioxidants such as β-mercaptoethanol; iii) a supplement for coenzyme transport in carboxyl group transfer reactions, such as biotin; iv) trace elements as a supplemental source of metal necessary for electron transport and many metalloenzymes and proteins, such as selenium; v) vitamins, such as biotin and pantotenate; and vi) ascorbic acid, to facilitate organization of the extracellular matrix.
Insulin and dexamethasone are added at the average concentrations usually reported in the literature. IGF-I, LIF and SCF are present at concentrations in the range from about
5 to about 10 ng/ml; preferably at a concentration of 5 ng/ml. All the other components are included in a range of concentration typically used in cell culture studies.
In a preferred embodiment of the composition suitable for the growth and proliferation of the chondrocytes, the defined components comprise EGF,
PDGFbb and FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), β-mercaptoethanol, dexamethasone, insulin, human holo- and apo- transferrin. In this embodiment, FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 1 to about 10 ng/ml. In a preferred embodiment, FGF-2, PDGFbb and EGF are present at concentrations of from
1 to 2 ng/ml.
In a preferred embodiment of the composition suitable for the growth and proliferation of the mesenchymal stem cells, the defined components comprise : EGF, PDGFbb and FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, β-mercaptoethanόl, dexamethasone, human holo- and apo- transferrin, selenium, biotin, sodium pantotenate. FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 5 ng/ml to- about 10 ng/ml of each factor. The preferred concentrations of FGF-2, PDGFbb and EGF are 10 ng/ml. FGF-2 alone was found to be the most active factor for maintenance of osteochondrogenic potential in MSCs.
Example 1 Articular cartilage was harvested from the knee joint of young adult human donors. The samples were first cleaned of any adherent muscular, connective or subchondral bone tissues, minced into l -3mm fragments and rinsed in PBS. Single chondrocytes were then released by repeated enzymatic digestions at 37°C with 0.25% trypsin, 400U/ml collagenase I, l OOOU/ml collagenase II and 1 mg/ml hyaluronidase. Trypsin was then blocked and removed by rapid and extensive washes in PBS containing soybean trypsin inhibitor. Cells were plated in anchorage-dependent conditions in Coon's modified Ham's F-12 medium supplemented either with 10% fetal calf serum (FCS, control culture) or the following defined components: EGF, PDGFbb and FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), β- mercaptoethanol, dexamethasone, insulin, human holo- and apo-transferrin.
Table 1 below shows the preferred amounts of each component. To favor adhesion of the cells in serum free conditions, the dishes were pre-coated with 2% gelatin.
Insulin may not be substituted with IGF-1 in the medium for chondrocytes. Insulin was preferably at a concentration of 5 μg/ml.
Selenium, biotin, sodium pantotenate and cholesterol can be routinely included but are optional. Table 1
Medium Supplement for Serum Free Expansion of Human Chondrocytes
INGREDIENT CONCENTRATION (Basal medium: Coon's modified Ham's F 12)
FGF-2 1 - 10 ng/ml
PDGFbb 1 - 10 ng/ml
EGF 1 - 10 ng/ml
Insulin 5 μg/ml Dexamethasone 10-8 M
Ascorbic Acid 50 μg/ml
Transferrin 20 - 50 μg/ml
HSA 1%
Linoleic Acid 6 μM β-mercaptoethanol 5xl 0"5M
Example 2
Bone marrow sample harvested from the iliac crest of the patient was washed twice with PBS. The nucleated cells were counted using methyl violet and plated at 5xl06 cells as unfractionated marrow per 10 cm tissue culture dish. For selection and expansion, the cells were maintained in Coon's modified Ham's F12 (F12) supplemented either with 10% FCS and 1 ng/ml
FGF-2 (control culture) or the following defined components: EGF, PDGFbb,
FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, β-mercaptoethanol, dexamethasone, human holo- and apo-transferrin, selenium, biotin and sodium pantotenate. Table 2 below shows the preferred amounts of each component.
To favor adhesion of the MSCs, the cells were first plated for 48 hours in F12 medium supplemented with 10% human serum and 1 ng/ml FGF-2.
Thereafter, the medium was removed and the cells were extensively washed with PBS, and left for an additional 24-48 hours in F12 medium without any supplement. The defined mixture of factors was then added to promote cell proliferation.
FGF-2 alone was the most active factor for maintenance of osteochondrogenic potential in mesenchymal stem cells. Selenium, biotin and sodium pantotenate were preferably included for cell viability. LIF and SCF were seen to improve the extent of cell proliferation, in particular in combination with IGF-1.
Table 2 Medium Supplement for Serum Free Expansion of MSCs INGREDIENT CONCENTRATION
(Basal medium: Coon's modified Ham's F12)
Human serum albumin 1-2%
Transferrin (apo/holo) 20 - 50 μg/ml
Ascorbic Acid 50 μg/ml β-mercaptoethanol 5 x 10-5M
Cholesterol 30 μg/ml
Selenium 30 nM
Biotin 33 μm
Na pantotenate 17 μM
EGF/PDGF/FGF-2 1 - 10 ng/ml
Dexamethasone 10"8M
IGF-I 5 ng/ml
LIF 5 ng/ml
SCF 5 ng/ml Studies have shown that PDGFbb by itself increases the osteogenic potential of MSCs when included in the phase of proliferation. This effect was found to be amplified by combining PDGFbb with FGF-2. Example 3
Growth Kinetics of Chondrocytes
At day 0, 5 x 10J first passage cells were plated in each well of a 24-well plate in the presence of FCS. Upon adhesion, the FCS was removed, and the cells were extensively washed with PBS and left for 2-3 days in F12 without supplement to exhaust residual traces of serum. Proliferation was then reinduced by adding either 10% FCS or the mixture of defined components established for chondrocytes. Cell number was evaluated at different days via
Thiazolyl blue (MTT) staining. Briefly, culture medium was removed and replaced with 0.5 ml of medium without supplement; then 25 μl MTT (Sigma,
St. Louis, MO) stock solution (5 mg/ml) was added to each culture being assayed. After a 3 hour incubation the medium was removed and the converted dye solubilized with absolute ethanol. Absorbance of converted dye was measured at a wavelength of 570 nm with background subtraction at 670 nm.
The data obtained (see Figure 1) clearly show that the defined medium induces the chondrocytes to proliferate to a rate and extent comparable to those obtained in the presence of FCS.
Example 4 The differentiation potential of the chondrocytes expanded in serum free conditions was tested both in vitro and in vivo. For in vitro assay, the expanded cells were transferred in anchorage-independent conditions and maintained as a pellet culture for 2-4 weeks in the serum free medium previously shown by Johnstone et al. (Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M. and Yoo, J.U. Exp. Cell Res. 238, 265-272, 1998) to induce chondrogenesis of serum expanded MSCs.
For in vivo assay, the expanded cells were implanted for 2 to 8- weeks in athymic mice either as a dense cell suspension or after embeddment in fibrin gel (Tissucol). At the term of the assays, the samples were fixed in formalin, embedded in paraffin and sectioned. Serial sections were processed for histological (toluidine blue and alcian blue) analysis and immunohistochemistry with collagen-specific antibodies. Results indicated that, at variance with chondrocytes expanded in the presence of FCS, the chondrocytes expanded in serum free conditions directly reformed a cartilaginous structure both in vitro and in vivo, which stained metachromatic for toluidine blue, positive for alcian blue and type II collagen, and mostly negative for type I collagen. In contrast, in the case of the expansion in FCS, a total absence of full chondrogensis was observed both in vitro and in vivo; at most, a faint metachromatic staining was detected in some pellet cultures, but they always lacked well defined lacunae and well organized extracellular matrix.
These data illustrate a major advantage of the serum free system that allows chondrogenesis without the requirement of additional culturing in the presence of TGF-β 1 or other factors (Johnstone's inducing conditions). This may be due to the fact that chondrocytes, in nature, are not in contact with serum which may contain elements that inhibit chondrogenesis.
Example 5 The osteogenic potential of MSCs after expansion under serum free defined conditions was tested in vivo by implantation of the expanded cells in athymic mice after adsorption on collagraft.
Several combinations of conditions were tested for bone formation in vivo. For all factor combinations, the medium contained Coon's modified Ham's F-12, dexamethasone, FGF-2, PDGFbb, EGF, transferrin, cholesterol, human serum albumin, biotin, selenium, Na pantotenate and ascorbic acid (concentrations as in Table 2). The combinations tested were 1) insulin; 2) IGF-1 ; 3) insulin and LIF; 4) insulin and SCF; 5) insulin, LIF and SCF; 6) IGF-1 and LIF; 7) IGF- 1 and SCF; and 8) IGF-1 , LIF and SCF.
After 8 weeks of implantation, the samples were decalcified, included and processed for histology as above. The sections were stained with hematoxylin-eosin. All the conditions of expansion allowed the MSCs to reform bone tissue in vivo; however, the amount of bone formed varied from condition to condition. The combination of IGF-1 , LIF and SCF provided an optimal expansion environment among the combinations tested.

Claims

1 . A serum free medium for cell culture, comprising a base minimum essential medium and a) one or more growth factors; and b) one or more sources of lipids and fatty acids.
2. The serum free medium of claim 1 , further comprising one or more steroids.
3. The serum free medium of claim 1 , further comprising a) albumin; b) an iron source; c) one or more antioxidants; d) a supplement for coenzyme transport in carboxyl group transfer reactions; e) trace elements; and f) vitamins.
4. The serum free medium of claim 1 wherein the growth factor is selected from the group consisting of insulin, FGF-2, PDGFbb, EGF, LIF and SCF and IGF-1.
5. The serum free medium of claim 2 wherein the steroid is dexamethasone.
6. The serum free medium of claim 1 wherein the lipid or fatty acid is cholesterol or linoleic acid.
7. The serum free medium of claim 3 wherein the albumin is human serum albumin.
8. The serum free medium of claim 3 wherein the iron source is transferrin.
9. The serum free medium of claim 8 wherein the iron source is human holo- or apo-transferrin.
10. The serum free medium of claim 3 wherein the antioxidant is β- mercaptoethanol or ascorbic acid.
1 1. The serum free medium of claim 3 wherein the supplement for coenzyme transport in carboxyl group transfer reactions is biotin.
12. The serum free medium of claim 3 wherein the trace element is selenium.
13. The serum free medium of claim 3 wherein the vitamin is biotin or pantotenate.
14. A composition for the expansion of chondrocytes, comprising FGF-2, a fatty acid source, ascorbic acid, dexamethasone and insulin.
15. A composition for the expansion of chondrocytes, comprising a minimum essential medium and EGF, PDGFbb and FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), β-mercaptoethanol, dexamethasone, insulin, human holo- and apo-transferrin.
16. A composition for the maintenance of mesenchymal stem cells, comprising selenium, biotin, sodium pantotenate, LIF, SCF and IGF-1.
17. A composition for the maintenance of mesenchymal stem cells comprising a minimum essential medium and EGF, PDGFbb, FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, β-mercaptoethanol, dexamethasone, human holo- and apo-transferrin, selenium, biotin and sodium pantotenate.
PCT/EP1999/008482 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells WO2000027996A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL14291499A IL142914A0 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells
JP2000581163A JP2002529071A (en) 1998-11-09 1999-11-08 Serum-free medium for chondrocyte-like cells
AU13804/00A AU758073B2 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells
US09/831,161 US6617159B1 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte cells
EP99971844A EP1131407B1 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells
CA002348687A CA2348687A1 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells
DE69933579T DE69933579D1 (en) 1998-11-09 1999-11-08 SERUM-FREE MEDIUM FOR CHONDROCYTE-SIMILAR CELLS
IL142914A IL142914A (en) 1998-11-09 2001-05-01 Serum free medium for chondrocyte-like cells
US10/614,191 US7109032B2 (en) 1998-11-09 2003-07-08 Serum-free medium for mesenchymal stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10764698P 1998-11-09 1998-11-09
US60/107,646 1998-11-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09831161 A-371-Of-International 1999-11-08
US10/614,191 Division US7109032B2 (en) 1998-11-09 2003-07-08 Serum-free medium for mesenchymal stem cells

Publications (1)

Publication Number Publication Date
WO2000027996A1 true WO2000027996A1 (en) 2000-05-18

Family

ID=22317692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008482 WO2000027996A1 (en) 1998-11-09 1999-11-08 Serum free medium for chondrocyte-like cells

Country Status (10)

Country Link
US (2) US6617159B1 (en)
EP (1) EP1131407B1 (en)
JP (1) JP2002529071A (en)
AT (1) ATE342348T1 (en)
AU (1) AU758073B2 (en)
CA (1) CA2348687A1 (en)
DE (1) DE69933579D1 (en)
IL (2) IL142914A0 (en)
RU (1) RU2272839C2 (en)
WO (1) WO2000027996A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828401A1 (en) * 2001-08-10 2003-02-14 Oreal Cosmetic composition useful for improving skin condition comprises insulin-like growth of specific factor or it's mimetic and ascorbic acid
JP2003052360A (en) * 2001-08-20 2003-02-25 Japan Science & Technology Corp Method for culturing mesenchymal stem cell using extracellular substrate of basement membrane cell
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
WO2004083415A1 (en) * 2003-03-17 2004-09-30 Biotissue Technologies Gmbh Cartilaginous cell culture medium and the use thereof
EP1478734A2 (en) * 2002-01-25 2004-11-24 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
WO2005012508A1 (en) * 2003-07-28 2005-02-10 Queensland University Of Technology Skin regeneration system
JPWO2003097820A1 (en) * 2002-05-22 2005-09-15 株式会社伏見製薬所 Method for utilizing physiological activity of rare sugar and composition containing rare sugar
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
EP1725656A1 (en) * 2004-03-05 2006-11-29 John E. Davies Serum-free suspension culture system for mesenchymal progenitor cells
EP1788076A1 (en) * 2005-11-16 2007-05-23 Cognis IP Management GmbH Use of esters of unsaturated physiologically active fatty acids as nutrient media for cell cultures
EP1820852A1 (en) * 2004-11-19 2007-08-22 JMS Co., Ltd. Human serum for cell culture
EP1881062A1 (en) * 2005-05-09 2008-01-23 Olympus Corporation Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue
EP1900810A1 (en) * 2006-09-15 2008-03-19 Celogos Method of extracting and selecting cells
EP1930413A1 (en) * 2005-08-23 2008-06-11 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
JP2008200520A (en) * 2002-03-06 2008-09-04 Univ Of Cincinnati Surgical device for skin therapy or testing
WO2008143884A2 (en) * 2007-05-14 2008-11-27 Cardiac Pacemakers, Inc. Media and devices for cold storage of therapeutic cells
WO2009030092A1 (en) * 2007-09-05 2009-03-12 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof
US7906330B2 (en) 2001-12-07 2011-03-15 Geron Corporation Two cell population comprising chondrocyte precursors and human embryonic stem cells
WO2011124894A1 (en) 2010-04-08 2011-10-13 The University Court Of The University Of Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
WO2013019661A1 (en) * 2011-07-29 2013-02-07 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
WO2015061839A1 (en) * 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
CN106459912A (en) * 2014-11-14 2017-02-22 再生医科学股份有限公司 Method for serum-free culture of cartilage cells and serum-free culture medium
US9644182B2 (en) 2001-04-24 2017-05-09 Dolores Baksh Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
WO2019072889A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Perfusion medium
WO2021158103A1 (en) * 2020-02-03 2021-08-12 Mosa Meat B.V. Serum-free medium for culturing a bovine progenitor cell.

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395271A1 (en) * 1999-12-28 2001-07-05 Isotis N.V. Cell culture medium containing growth factors and l-glutamine
US20070141036A1 (en) * 2002-01-09 2007-06-21 Alberto Gorrochategui Barrueta Composition and procedure for tissue creation, regeneration and repair by a cell-bearing biological implant enriched with platelet concentrate and supplements
WO2005065354A2 (en) * 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
WO2006004149A1 (en) * 2004-07-06 2006-01-12 Kyowa Hakko Kogyo Co., Ltd. Method of producing nerve cell
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
JP4646600B2 (en) * 2004-11-02 2011-03-09 オリンパス株式会社 Method for culturing mesenchymal stem cells
JP2006136281A (en) * 2004-11-15 2006-06-01 Olympus Corp Medium and method for culturing mesenchymal stem cell
US20090169523A1 (en) 2005-06-13 2009-07-02 Catherine Verfaillie Hsc self-renewal
JP4921083B2 (en) * 2005-09-13 2012-04-18 タカラバイオ株式会社 Serum-free medium for retrovirus production
WO2007044418A2 (en) * 2005-10-06 2007-04-19 Moscatello David K Cell culture media, kits and methods of use
EP1988159B1 (en) 2006-01-13 2014-03-05 Two Cells Co., Ltd. Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit
ITTO20060282A1 (en) * 2006-04-14 2007-10-15 Univ Degli Studi Torino MEDIUM OF CULTURE AND PHARMACEUTICAL COMPOSITION FOR THE REGENERATION OF THE RELATIVE PAPER FABRIC PROCEDURE RELATED TO USES AND PRODUCTS
BRPI0713572A2 (en) * 2006-06-20 2012-10-23 Stephen Duguay serum free media and their uses for chondrocyte expansion
JP2008099662A (en) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research Method for culturing stem cell
EP1972685B1 (en) * 2007-03-20 2015-09-02 Université Paris Descartes Culture medium for gingival fibroblasts
ITMI20071421A1 (en) * 2007-07-16 2009-01-17 Fond Irccs Istituto Di Ricove CULTURE TO EXPAND EX-LIVE STEM CELLS
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
US20100015710A1 (en) * 2008-04-25 2010-01-21 Sunghoon Jung Methods and Compositions for Isolating, Maintaining and Serially Expanding Human Mesenchymal Stem Cells
ES2697798T3 (en) * 2008-06-30 2019-01-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
AU2009315204B2 (en) 2008-11-11 2015-03-26 Two Cells Co., Ltd. Additive for differentiation induction culture medium, and use thereof
SG10201404281YA (en) 2009-07-21 2014-09-26 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
US20110020293A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of Stem Cells to Reduce Leukocyte Extravasation
WO2011010966A1 (en) * 2009-07-23 2011-01-27 Agency For Science, Technology And Research (A*Star) Pre-natal mesenchymal stem cells
CA3174901A1 (en) * 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
SG10201914001QA (en) 2010-02-25 2020-03-30 Abt Holding Co Modulation of macrophage activation
EP2539439B1 (en) 2010-02-25 2018-10-17 ABT Holding Company Modulation of angiogenesis
US9394521B2 (en) 2010-03-10 2016-07-19 Two Cells Co., Ltd. Cell preparation containing mesenchymal stem cells, and method for producing same
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011158125A2 (en) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
US8609406B2 (en) 2010-08-24 2013-12-17 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012104731A2 (en) 2011-01-31 2012-08-09 Katholieke Universiteit Leuven Methods for making cells with an extra-embryonic endodermal precursor phenotype
DK2718416T3 (en) 2011-06-06 2020-02-24 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
RU2461623C1 (en) * 2011-06-20 2012-09-20 Борис Карпович Гаврилюк Method for cartilage cell culture
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
GB201119335D0 (en) 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
US9321995B2 (en) * 2012-12-20 2016-04-26 Suzhou Biowisetech Co., Ltd. Stem cell culture medium and its applications as well as a stem cell culture method
WO2014146057A2 (en) * 2013-03-15 2014-09-18 Cmr Technologies, Llc Mesenchymal stem cells
CN115177637A (en) 2013-04-12 2022-10-14 休斯顿卫理公会医院 Improvements in organs for transplantation
AU2014266935B2 (en) 2013-04-30 2020-06-11 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
JP6512759B2 (en) * 2013-08-19 2019-05-15 国立研究開発法人国立循環器病研究センター Method of producing amniotic mesenchymal cell composition, method of cryopreservation, and therapeutic agent
CN105992816B (en) 2013-11-16 2018-04-17 泰尔茂比司特公司 Cell amplification in bioreactor
CN103805562B (en) * 2014-01-13 2015-08-05 章毅 Cultivate the serum free medium of placenta mesenchyma stem cell
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
US9433629B2 (en) 2014-05-23 2016-09-06 Juan Paz Garcia Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts
US9669074B2 (en) * 2014-05-23 2017-06-06 Juan Paz Garcia Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts
AU2015264043B2 (en) * 2014-05-23 2020-08-13 Regen Therapies, Inc. Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
CN107567494A (en) * 2015-03-04 2018-01-09 迈索布拉斯特国际有限公司 The cell culture processes of mescenchymal stem cell
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10967006B2 (en) 2016-01-21 2021-04-06 Abt Holding Company Stem cells for wound healing
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11180733B2 (en) 2016-07-04 2021-11-23 Agency For Science, Technology And Research Method of generating mesenchymal stem cells and uses thereof
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7372518B2 (en) 2019-06-27 2023-11-01 国立大学法人山口大学 Method for culturing bone marrow-derived mesenchymal stem cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
WO1996039487A1 (en) * 1995-06-05 1996-12-12 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
WO1996040866A1 (en) * 1995-06-07 1996-12-19 Novartis Ag Serum-free media for primitive hematopoietic cells and methods of use thereof
WO1997033978A1 (en) * 1996-03-12 1997-09-18 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
WO1998004681A2 (en) * 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
WO1998032333A1 (en) * 1996-12-06 1998-07-30 Osiris Therapeutics, Inc. Improved chondrogenic differentiation of human mesenchymal stem cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
WO1996039487A1 (en) * 1995-06-05 1996-12-12 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
WO1996040866A1 (en) * 1995-06-07 1996-12-19 Novartis Ag Serum-free media for primitive hematopoietic cells and methods of use thereof
WO1997033978A1 (en) * 1996-03-12 1997-09-18 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
WO1998004681A2 (en) * 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
WO1998032333A1 (en) * 1996-12-06 1998-07-30 Osiris Therapeutics, Inc. Improved chondrogenic differentiation of human mesenchymal stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAIN B ET AL: "LONG-TERM IN VITRO CULTURE AND CHARACTERISATION OF AVIAN EMBRYONIC STEM CELLS WITH MULTIPLE MORPHOGENETIC POTENTIALITIES", DEVELOPMENT,GB,COLCHESTER, ESSEX, vol. 122, August 1996 (1996-08-01), pages 2239 - 2248, XP002913043, ISSN: 0950-1991 *
QUARTO R ET AL: "Proliferation and differentiation of chondrocytes in defined culture medium: effects of systemic factors", BONE, vol. 17, no. 6, December 1995 (1995-12-01), pages 558, XP000891633 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9644182B2 (en) 2001-04-24 2017-05-09 Dolores Baksh Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
WO2003013464A1 (en) * 2001-08-10 2003-02-20 L'oreal Composition comprising an association between igf1 and the ascorbic acid
FR2828401A1 (en) * 2001-08-10 2003-02-14 Oreal Cosmetic composition useful for improving skin condition comprises insulin-like growth of specific factor or it's mimetic and ascorbic acid
JP2003052360A (en) * 2001-08-20 2003-02-25 Japan Science & Technology Corp Method for culturing mesenchymal stem cell using extracellular substrate of basement membrane cell
US7906330B2 (en) 2001-12-07 2011-03-15 Geron Corporation Two cell population comprising chondrocyte precursors and human embryonic stem cells
US8546101B2 (en) 2001-12-07 2013-10-01 Geron Corporation Compound screening using chondrocytes derived from primate pluripotent stem cells
EP1478734A4 (en) * 2002-01-25 2006-04-05 Genzyme Corp Serum-free media for chondrocytes and methods of use thereof
EP1478734A2 (en) * 2002-01-25 2004-11-24 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7169610B2 (en) 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US8765468B2 (en) 2002-03-06 2014-07-01 University Of Cincinnati Surgical device for skin therapy or testing
JP2008200520A (en) * 2002-03-06 2008-09-04 Univ Of Cincinnati Surgical device for skin therapy or testing
US8450108B2 (en) 2002-03-06 2013-05-28 University Of Cincinnati Surgical device for skin therapy or testing
US9089417B2 (en) 2002-03-06 2015-07-28 Steven T. Boyce Surgical device for skin therapy or testing
JP4554940B2 (en) * 2002-04-03 2010-09-29 直秀 山下 Medicament containing mesenchymal cells derived from human placenta and method for producing VEGF using the cells
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
JPWO2003082305A1 (en) * 2002-04-03 2005-07-28 直秀 山下 Medicament containing mesenchymal cells derived from human placenta and method for producing VEGF using the cells
JPWO2003097820A1 (en) * 2002-05-22 2005-09-15 株式会社伏見製薬所 Method for utilizing physiological activity of rare sugar and composition containing rare sugar
WO2004083415A1 (en) * 2003-03-17 2004-09-30 Biotissue Technologies Gmbh Cartilaginous cell culture medium and the use thereof
WO2005012508A1 (en) * 2003-07-28 2005-02-10 Queensland University Of Technology Skin regeneration system
US8911997B2 (en) 2003-07-28 2014-12-16 Queensland University Of Technology Mammalian cell culture medium
EP1725656A1 (en) * 2004-03-05 2006-11-29 John E. Davies Serum-free suspension culture system for mesenchymal progenitor cells
EP1725656A4 (en) * 2004-03-05 2007-10-03 John E Davies Serum-free suspension culture system for mesenchymal progenitor cells
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
EP1820852A1 (en) * 2004-11-19 2007-08-22 JMS Co., Ltd. Human serum for cell culture
EP1820852A4 (en) * 2004-11-19 2007-11-14 Jms Co Ltd Human serum for cell culture
US8679838B2 (en) 2004-11-19 2014-03-25 Jms Co., Ltd. Human serum for cell culture
US7972767B2 (en) 2005-05-09 2011-07-05 Olympus Corporation Method for culturing mesenchymal stem cell and method for producing biological tissue prosthesis
EP1881062A4 (en) * 2005-05-09 2009-03-11 Olympus Corp Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue
EP1881062A1 (en) * 2005-05-09 2008-01-23 Olympus Corporation Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue
EP1930413A1 (en) * 2005-08-23 2008-06-11 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
US8728814B2 (en) 2005-08-23 2014-05-20 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
EP1930413A4 (en) * 2005-08-23 2008-12-17 Oriental Yeast Co Ltd Technique for culture of mesenchymal stem cell utilizing laminin-5
EP1788076A1 (en) * 2005-11-16 2007-05-23 Cognis IP Management GmbH Use of esters of unsaturated physiologically active fatty acids as nutrient media for cell cultures
WO2008031957A3 (en) * 2006-09-15 2008-07-03 Celogos Method for extracting and selecting cells
EP1900810A1 (en) * 2006-09-15 2008-03-19 Celogos Method of extracting and selecting cells
WO2008031957A2 (en) * 2006-09-15 2008-03-20 Celogos Method for extracting and selecting cells
WO2008143884A3 (en) * 2007-05-14 2009-09-03 Cardiac Pacemakers, Inc. Media and devices for cold storage of therapeutic cells
WO2008143884A2 (en) * 2007-05-14 2008-11-27 Cardiac Pacemakers, Inc. Media and devices for cold storage of therapeutic cells
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
WO2009030092A1 (en) * 2007-09-05 2009-03-12 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof
WO2011124894A1 (en) 2010-04-08 2011-10-13 The University Court Of The University Of Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
US9029145B2 (en) 2010-04-08 2015-05-12 The University Court Of The University Of Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
US9725697B2 (en) 2010-04-08 2017-08-08 The University Court Of The University Of Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
WO2013019661A1 (en) * 2011-07-29 2013-02-07 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
US9034584B2 (en) 2011-07-29 2015-05-19 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
WO2015061839A1 (en) * 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
AU2014344795B2 (en) * 2013-11-04 2016-05-26 Isopogen Pty Ltd Cell culture method
US9868936B2 (en) 2013-11-04 2018-01-16 Isopogen Pty Ltd Cell culture method
US11041144B2 (en) 2013-11-04 2021-06-22 Isopogen Pty Ltd Cell culture method
CN106459912A (en) * 2014-11-14 2017-02-22 再生医科学股份有限公司 Method for serum-free culture of cartilage cells and serum-free culture medium
EP3219792A4 (en) * 2014-11-14 2018-04-11 Regenesis Science Co. Ltd. Method for serum-free culture of cartilage cells and serum-free culture medium
EP3536778A1 (en) * 2014-11-14 2019-09-11 Regenesis Science Co. Ltd. Method for serum-free culture of chondrocytes and serum-free culture medium
CN106459912B (en) * 2014-11-14 2021-05-25 再生医科学股份有限公司 Serum-free culture method and serum-free culture medium for chondrocytes
US11427808B2 (en) 2014-11-14 2022-08-30 Regenesis Science Co., Ltd. Method for serum-free culture of chondrocytes and serum-free culture medium
WO2019072889A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Perfusion medium
WO2021158103A1 (en) * 2020-02-03 2021-08-12 Mosa Meat B.V. Serum-free medium for culturing a bovine progenitor cell.

Also Published As

Publication number Publication date
AU1380400A (en) 2000-05-29
CA2348687A1 (en) 2000-05-18
JP2002529071A (en) 2002-09-10
US6617159B1 (en) 2003-09-09
ATE342348T1 (en) 2006-11-15
IL142914A0 (en) 2002-04-21
US20050090002A1 (en) 2005-04-28
US7109032B2 (en) 2006-09-19
AU758073B2 (en) 2003-03-13
RU2272839C2 (en) 2006-03-27
IL142914A (en) 2006-07-05
EP1131407A1 (en) 2001-09-12
EP1131407B1 (en) 2006-10-11
DE69933579D1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
AU758073B2 (en) Serum free medium for chondrocyte-like cells
EP1988159B1 (en) Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit
US6709864B1 (en) Adipogenic differentiation of human mesenchymal stem cells
EP1018987B1 (en) Neocartilage and methods of use
US6730314B2 (en) Culturing encapsulated chondrocytes under reduced oxygen partial pressure to produce cartilage implants
CN101412985A (en) Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells
US20080187518A1 (en) Production of Osteoclasts from Adipose Tissues
WO2021254296A1 (en) Bioactive substance composition, serum-free culture medium comprising the composition, and uses thereof
US20230117670A1 (en) Bioactive substance composition, serum-free medium comprising the composition, and uses thereof
US11840706B2 (en) Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells
CANALIS et al. Effect of partially purified bone morphogenetic protein on DNA synthesis and cell replication in calvarial and fibroblast cultures.
Hendriks et al. Effect of stratified culture compared to confluent culture in monolayer on proliferation and differentiation of human articular chondrocytes
O'Keefe et al. Countercurrent centrifugal elutriation. High-resolution method for the separation of growth-plate chondrocytes.
KR101503939B1 (en) Method for preparation of cartilage cell
KR100394430B1 (en) Medium for culturing human cell comprising human serum and method for culturing human cell using same
SHIMOMURA et al. Cultured growth cartilage cells.
JP2007000077A (en) Method for serum-free culture of adherent animal cell and culture medium for serum-free culture of adherent animal cell
US20070004037A1 (en) Methods and compositions for culturing keratinocytes
Suryawan et al. The primary cell culture system for preadipocytes
Zamani et al. Comparison of cartilage specific markers in articular and differentiated chondrocytes in pellet system.
CN112410296A (en) Serum-free cell culture medium
Collodi et al. Serum-free media
MXPA97005612A (en) Induction directed by lineage of the differentiation of human mesenquimatosas cells of ori

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 13804

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2348687

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2348687

WWE Wipo information: entry into national phase

Ref document number: 142914

Country of ref document: IL

Ref document number: 13804/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999971844

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 581163

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09831161

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999971844

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 13804/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999971844

Country of ref document: EP